Sign in

You're signed outSign in or to get full access.

WG

Wag! Group Co. (PET)·Q2 2024 Earnings Summary

Executive Summary

  • Q2 revenue declined 6% year over year to $18.65M as management deliberately scaled back marketing to prioritize profitability; Adjusted EBITDA reached a record $1.64M (8.8% margin), up from $0.11M (0.5% margin) a year ago .
  • Management reiterated the July 10 reset of FY24 guidance: revenue cut to $92–$102M (from $105–$115M) while Adjusted EBITDA was raised to $4–$8M; Q3 guidance calls for $20–$24M revenue and $1.5–$2.5M Adjusted EBITDA, with expected positive free cash flow in 2H24 .
  • Balance sheet actions are the key near-term catalyst: $10M equity raise in July, planned debt paydown/refinance (current rate 15.8% targeted to ~10%), and ~$340K quarterly interest savings beginning in Q3; combined cash and AR ended Q2 at ~$17M .
  • S&P Global consensus estimates for Q2 2024 were unavailable for PET; as a result, a formal beat/miss analysis versus Street consensus cannot be provided (estimates unavailable via S&P Global).

What Went Well and What Went Wrong

  • What Went Well

    • Record profitability: Adjusted EBITDA of $1.64M (8.8% margin) on $18.65M revenue, driven by reduced/optimized marketing and operational efficiencies .
    • Disciplined cost structure: Platform ops 15% of revenue (vs. 18% YoY), G&A 20% (vs. 24% YoY), with AI and automation improving efficiency; S&M cut to 59% from 67% in Q1 2024 .
    • Clear deleveraging path: $10M equity raise, debt paydown/refi expected 2H24, target debt rate ~10% (from 15.8%), ~$340K quarterly interest savings from Q3 .
    • Quote: “Our results were highly intentional as we reduced marketing spend to increase profitability… our adjusted EBITDA increased to $1.6 million, a quarterly record” .
  • What Went Wrong

    • Top-line contraction and engagement pressure: Revenue -6% YoY to $18.65M and platform participants -15% YoY to 467K as marketing was curtailed and mix shifted toward returning users .
    • Sequential revenue decline: From a record Q1 ($23.22M) to Q2 ($18.65M), reflecting deliberate pullback in spend and seasonality/mix .
    • Services headwinds and macro/marketing environment: Management flagged a tougher paid media backdrop (election-year CPM/CPC pressure) and is shifting toward partnerships and non-Google/Facebook channels .

Financial Results

MetricQ2 2023Q4 2023Q1 2024Q2 2024
Revenue ($USD Millions)$19.820 $21.673 $23.219 $18.651
GAAP Diluted EPS ($)$(0.10) $(0.09) $(0.11) $(0.06)
Net Loss Margin %(19.5)% (16.0)% (18.3)% (12.1)%
Adjusted EBITDA ($USD Millions)$0.107 $0.005 $0.168 $1.639
Adjusted EBITDA Margin %0.5% 0.7% 8.8%

Segment revenue trend

Segment ($USD Millions)Q4 2023Q1 2024Q2 2024
Services$6.3 $5.3 $5.6
Wellness$13.5 $15.8 $11.5
Pet Food & Treats$1.9 $2.1 $1.5
Total Revenue$21.7 $23.2 $18.7

Operating mix and KPIs

KPI / MixQ4 2023Q1 2024Q2 2024
Platform Participants (000s)600 671 467
Sales & Marketing as % of Revenue63% 67% 59%
Platform Ops & Support as % of Revenue13% 13% 15%
G&A as % of Revenue22% 18% 20%
Cash + AR (period-end, $M)$28.35 (cash+AR) $23.71 (cash+AR) ~$17 (cash, cash equivalents and AR)

Notes:

  • Q2 revenue decreased 6% YoY to $18.651M; net loss improved to $(2.251)M; Adjusted EBITDA improved to $1.639M (8.8% margin) .
  • Decline in Platform Participants reflects mix shift as marketing was reduced; ARPU increased per management commentary, but a specific figure was not disclosed .

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
RevenueFY 2024$105M–$115M (May 9) $92M–$102M (July 10; reiterated Aug 7) Lowered
Adjusted EBITDAFY 2024$2M–$6M (May 9) $4M–$8M (July 10; reiterated Aug 7) Raised
Free Cash Flow2H 2024Positive (implied from May 9 guide) Positive reiterated Maintained
RevenueQ3 2024$20M–$24M New quarterly guide
Adjusted EBITDAQ3 2024$1.5M–$2.5M New quarterly guide

Management context:

  • Rationale for FY guidance reset: reduce near-term marketing to prioritize profitability and balance sheet flexibility ahead of debt refi; marketing efficiency expected to improve and re-accelerate post-refi .

Earnings Call Themes & Trends

TopicPrevious Mentions (Q4’23 and Q1’24)Current Period (Q2’24)Trend
Profitability focus and marketing disciplineQ4: Leaned into S&M in Dec; FY24 guide implied reinvestment; efficiency gains highlighted . Q1: Record revenue, small positive Adj. EBITDA; flagged elevated CPC/CPM into election year .Intentional S&M pullback drove record Adj. EBITDA; S&M % fell to 59% from 67% in Q1 .Toward profitability near-term; plan to re-accelerate after refi .
Debt reduction/refinanceQ4: Authorized up to $10M debt paydown in 2024 . Q1: Paid down $5M; one-time extinguishment costs .$10M equity raise; refi targeted in 2H; rate goal ~10% from 15.8%; ~$340K quarterly interest savings starting Q3 .Balance sheet de-risking; interest burden to ease .
Wellness and premium pet demandQ4: Wellness growth strong; secular tailwinds . Q1: Wellness $15.8M; durable premium demand .Wellness $11.5M; mgmt says premium wellness demand remains durable amid macro noise .Remains core growth engine .
New products: Furscription (Rx SaaS) & WeCompareQ1: Launched Furscription beta; WeCompare to start with auto insurance; 2025 heavier contribution .Expect a more fulsome Furscription update next call; WeCompare ramp mostly 2025 given current marketing bandwidth .Execution pacing toward 2025 scale .
Marketing channels and partnershipsQ1: Noted election-year CPM/CPC pressure .Shift toward partnerships/non-Google/Facebook; aim for more durable, organic-like acquisition .Channel mix pivot to higher-ROI routes .

Management Commentary

  • Strategic priority: “Strengthening our balance sheet and demonstrating consistent profitability is going to be utmost importance… we believe we’ll be in a position to deliver positive free cash flow going forward” .
  • Cost discipline: “Platform operations and support… 15% of revenue versus 18% a year ago… Sales and marketing… 59% of revenue, up from 54% a year ago, but down from 67% in Q1” .
  • Debt and interest: “We plan to use the [equity] proceeds to pay down high interest debt… approximately $340,000 of quarterly interest cost savings starting in Q3… we think… we can get to a rate closer to 10% [from 15.8%]” .
  • Growth vs. profit: “As we return to growth, we expect to maintain a healthy adjusted EBITDA margin to balance profitability and growth going forward” .
  • Product strategy: “We’re very excited about the long-term growth prospects of our prescription B2B SaaS platform… WeCompare… majority of the growth contribution to come in 2025” .

Q&A Highlights

  • Timing of re-accelerating marketing: Management will first refi debt; then lean back into growth in late 2024 with a more balanced approach to EBITDA margins (targeting ~8–12% in 2025) .
  • Demand backdrop: Premium pet wellness remains durable despite macro volatility; sequential improvement expected in Q3 vs. Q2 .
  • Marketing ROI and channels: Election-year ad environment is tougher; shifting to partnerships and non-search/social routes for better ROI and durability .
  • ARPU/Customer mix: Pullback in marketing tilts mix to returning customers with higher ARPU; increased emphasis on upsell/cross-sell within platform .
  • G&A scaling: G&A will not scale linearly with revenue as growth returns; efficiencies in headcount/tech to continue .

Estimates Context

  • S&P Global consensus estimates for PET’s Q2 2024 revenue and EPS were unavailable via our S&P Global feed at this time; therefore, we cannot quantify a beat or miss versus consensus. We will update comparisons if/when S&P Global estimates become available.

Key Takeaways for Investors

  • Record Adjusted EBITDA with sharply improved margin demonstrates operating leverage available when marketing is dialed back; this sets a higher profitability baseline for post-refi growth .
  • The debt refinancing is the pivotal catalyst: expected 2H24 close, interest rate potentially dropping toward ~10% from 15.8%, with ~$340K/qtr interest savings starting Q3; equity proceeds already raised to facilitate paydown .
  • FY24 guidance reset lowers revenue but raises EBITDA, signaling a deliberate pivot to cash generation and balance sheet health; positive FCF expected in 2H24 .
  • Near-term growth may remain constrained until refi is finalized; watch Q3 delivery against $20–$24M revenue and $1.5–$2.5M Adjusted EBITDA guide for confirmation of trajectory .
  • Wellness remains the structural growth pillar; Services should benefit if return-to-office trends improve and as channel strategy pivots to partnerships .
  • 2025 setup: Expect renewed growth investment with a higher EBITDA margin target range (8–12%) as the company balances expansion with sustained profitability .